News - Tasigna


Current filters:


Popular Filters

"NICE" news for Novartis CML drugs, but not for Bristol-Myers


In final draft guidance issued this morning, UK drugs watchdog the National Institute for Health and…

Bristol-Myers SquibbEuropeGlivecNovartisOncologyPharmaceuticalPricingRegulationSprycelTasigna

Mixed NICE recommendations for CML and diabetes drugs


In a batch of final guidances released this morning by the UK’s drug watchdog the Institute for…

Bristol-Myers SquibbBydureonDiabetesEli LillyEuropeGlivecNovartisOncologyPharmaceuticalPricingRegulationSprycelTasigna

More news for ASH meeting


In continuing news from the 53rd annual meeting of the American Society of Hematology (ASH) in San Diego,…

Avila TherapeuticsGleevecNovartisOncologypacritinibPharmaceuticalResearchS*BIOTasigna

UK’s NICE says “no” to Novartis Tasigna and B-MS Sprycel, but better news on Afinitor


The UK’s drug rationing body the National Institute for Health and Clinical Excellence (NICE) yesterday…

AfinitorBristol-Myers SquibbGlivecNovartisOncologyPharmaceuticalPricingRegulationSprycelTasigna

Back to top